keyword
MENU ▼
Read by QxMD icon Read
search

Dupilumab

keyword
https://www.readbyqxmd.com/read/29451112/-regained-freedom-for-patients-with-atopic-dermatitis-fast-and-long-term-effects-of-dupilumab
#1
T Nijsten, D J Hijnen
Dupilumab is the first and long-awaited biological for treatment of moderate to severe atopic dermatitis. In randomised clinical trials approximately 40% of patients using dupilumab 300 mg every two weeks were clear or almost clear of their eczema after 16 and 52 weeks. We now face the challenge of patient stratification to limit the budget impact of dupilumab and hope that more targeted therapies for atopic dermatitis will follow soon.
2018: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29441557/impact-of-dupilumab-on-health-related-quality-of-life-in-patients-with-atopic-dermatitis
#2
F Rencz
No abstract text is available yet for this article.
February 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29433635/-current-and-upcoming-treatments-of-adult-atopic-dermatitis
#3
J-P Lacour
The treatment of atopic dermatitis in adults is based on the use of topical steroids and emollients. When AD is resistant to a well-conducted topical treatment, phototherapy or systemic treatments can be used: ciclosporin, methotrexate, azathioprine or mycophenolate mofetil. The therapeutic landscape of adult AD is about to change and even be revolutionized by the imminent arrival of new treatments: topical phosphodiesterase 4 inhibitors, topical or systemic JAK inhibitors, anti-IL-4 and/or antiIL-13 biotherapies (dupilumab, tralokinumab, lebrikizumab), anti-IL-31 (nemolizumab), anti-TSLP...
December 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29432961/conjunctivitis-occurring-in-atopic-dermatitis-patients-treated-with-dupilumab-clinical-characteristics-and-treatment
#4
Andreas Wollenberg, Lieneke Ariens, Stephan Thurau, Chantal van Luijk, Marlene Seegräber, Marjolein de Bruin-Weller
No abstract text is available yet for this article.
February 9, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29422431/dupilumab-for-the-treatment-of-atopic-dermatitis
#5
S Ferreira, T Torres
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. AD usually starts in early childhood and has a heterogeneous course. Emerging evidence suggests that IL-4 and IL-13 are key cytokines in the immunopathogenesis of AD. Dupilumab is a monoclonal antibody directed against IL-4 receptor α subunit, that blocks both IL-4 and IL-13 signaling. Data from Phase I-III studies revealed that dupilumab, administered as monotherapy or with topical corticosteroids, is effective and well tolerated in the treatment of adult patients with moderate-to-severe AD...
February 5, 2018: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/29416367/profile-of-dupilumab-and-its-potential-in-the-treatment-of-inadequately-controlled-moderate-to-severe-atopic-dermatitis
#6
REVIEW
Olabola Awosika, Lori Kim, Momina Mazhar, Monica Rengifo-Pardo, Alison Ehrlich
Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13...
2018: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29387767/alopecia-areata-after-dupilumab-for-atopic-dermatitis
#7
Krystal Mitchell, Jacob Levitt
No abstract text is available yet for this article.
March 2018: JAAD Case Reports
https://www.readbyqxmd.com/read/29355679/efficacy-and-safety-of-dupilumab-in-perennial-allergic-rhinitis-and-comorbid-asthma
#8
Steven F Weinstein, Rohit Katial, Shyamalie Jayawardena, Gianluca Pirozzi, Heribert Staudinger, Laurent Eckert, Vijay N Joish, Nikhil Amin, Jaman Maroni, Paul Rowe, Neil M H Graham, Ariel Teper
BACKGROUND: Dupilumab, an anti-IL-4Rα monoclonal antibody, inhibits IL-4/IL-13 signaling, key drivers of type 2/Th2 immune diseases (e.g. atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2-agonists. OBJECTIVE: To examine dupilumab's effect on the 22-item Sino-Nasal Outcome Test (SNOT-22) total score and its allergic rhinitis (AR)-associated items in asthma patients with comorbid perennial allergic rhinitis (PAR)...
January 17, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29315479/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and-concomitant-topical-corticosteroids-liberty-ad-chronos-a-critical-appraisal
#9
J Thomson, A G H Wernham, H C Williams
AIM: Blauvelt et al. (The Lancet 2017; 389: 2287-303) aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) versus placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD). SETTING AND DESIGN: This multicentre randomised, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries. STUDY EXPOSURE: Adults with moderate-to-severe AD were randomly assigned (3:1:3) to receive subcutaneous dupilumab 300mg once weekly (qw) plus TCS, dupilumab 300mg every 2 weeks (q2w) plus TCS, or placebo plus TCS until week-52...
January 6, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29312544/efficacy-and-safety-of-dupilumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults
#10
Xinghua Xu, Yi Zheng, Xin Zhang, Yanling He, Chengxin Li
Objective: Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, excoriations and limited therapies. Dupilumab, a monoclonal antibody against interleukin-4 receptor alpha, is a promising new treatment option for atopic dermatitis. We sought to systematically summarize the efficacy, safety, and influence on quality of life of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Results: A total of 7 RCTs containing 2705 subjects were identified...
December 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29304565/food-and-drug-administration-approval-process-for-dermatology-drugs-in-the-united-states
#11
Emily Boozalis, Yevgeniy R Semenov, Shawn G Kwatra
AIM: The purpose of this review is to elucidate the steps involved in the FDA's approval of new dermatology drugs. METHODS: To help illustrate the process of drug approval, we use examples from the recent approval of dupilumab (REGN668; Regeneron Pharmaceuticals). RESULTS: In general, new dermatology drugs must undergo pre-clinical studies on non-human subjects and three phases of clinical trials in humans before undergoing review by the Food and Drug Administration (FDA)...
January 26, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29300693/antibodies-to-watch-in-2018
#12
Hélène Kaplon, Janice M Reichert
The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United States (US) reached double-digits (total of 10) for the first time in 2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab, guselkumab, benralizumab, ocrelizumab, inotuzumab ozogamicin, avelumab, duvalumab, and emicizumab. Brodalumab, however, had already been approved in Japan in 2016...
January 4, 2018: MAbs
https://www.readbyqxmd.com/read/29260094/cicatricial-ectropion-in-a-patient-treated-with-dupilumab
#13
Alexander C Barnes, Alexander D Blandford, Julian D Perry
Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two months after starting weekly dupilumab injections for atopic dermatitis. The findings worsened over the next several months and improved after discontinuing dupilumab. Conclusions and importance: Dupilumab is a promising intervention in the management of atopic dermatitis and asthma, however, little is known about its potential ocular adverse effects...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29249252/-what-s-new-in-dermatological-treatment
#14
M Viguier
On a therapeutic point of view, 2017 in dermatology could be summarized in one disease, one pathway and in one number : atopic dermatitis, JAK inhibitors and 23. 2017 will be the year of the first registration of a biologic treatment in atopic dermatitis, dupilumab, with numerous other drugs currently in development. JAK inhibitors show promising results in several difficult-to-treat conditions, such as alopecia areata, vitiligo or atopic dermatitis, but still warrant confirmation in upcoming controlled trials...
December 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29248519/t-cell-inhibitors-for-atopic-dermatitis
#15
W James Tidwell, Joseph F Fowler
The management of atopic dermatitis is changing with the development of novel biological agents to target specific molecules in the inflammatory cascade. Dupilumab has proven its ability to act on the IL-4 receptor in treating atopic dermatitis. Thymic stromal lymphopoietin (TSLP) monoclonal antibody (AMG157/ MEDI9929) and OX40 blocking antibody (GBR 830) were developed by target the same pathway as dupilumab. The clinical data on the efficacy for these drugs is not yet known. There is some early evidence that AMG157/ MEDI9929 attenuates most measures of allergen-induced asthmatic responses...
December 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29238761/dupilumab-human-monoclonal-antibody-against-il-4r%C3%AE-for-moderate-to-severe-atopic-dermatitis
#16
D M Paton
Atopic dermatitis (AD) is one of the most common skin disorders with a prevalence of about 20% in children and affecting adults in significant numbers. Moderate to severe AD significantly impairs a patient's quality of life with severe pruritus as a major issue that impairs sleep and contributes to major psychological disturbances. Detailed studies of its pathogenesis have revealed that immune mechanisms are involved including activation of T helper type 2 cells (Th2). Dupilumab is a fully human Ig4 monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13 receptors...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29237258/diagnosis-and-management-of-moderate-to-severe-adult-atopic-dermatitis-a-consensus-by-the-italian-society-of-dermatology-and-venereology-sidemast-the-italian-association-of-hospital-dermatologists-adoi-the-italian-society-of-allergy-asthma-and-clinical-immunology
#17
Piergiacomo Calzavara Pinton, Antonio Cristaudo, Caterina Foti, Giorgio W Canonica, Nicola Balato, Antonio Costanzo, Ornella DE Pità, Clara DE Simone, Cataldo Patruno, Giovanni Pellacani, Ketty Peris, Giampiero Girolomoni
Atopic dermatitis (AD) is a chronic immune-mediated inflammatory skin disease, currently recognized as a systemic disease possibly burdened by various comorbidities, including, but not limited to, other allergic conditions. Management guidelines issued by American and European dermatology and allergy scientific societies are available. However, some discrepancies exist in these guidelines, and some aspects of the management process, including diagnosis and severity assessment, as well as therapy duration and switch criteria, are not fully clarified by existing guidelines...
December 14, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29193016/dupilumab-with-concomitant-topical-corticosteroids-in-adult-patients-with-atopic-dermatitis-who-are-not-adequately-controlled-with-or-are-intolerant-to-ciclosporin-a-or-when-this-treatment-is-medically-inadvisable-a-placebo-controlled-randomized-phase-3-clinical
#18
M de Bruin-Weller, D Thaçi, C H Smith, K Reich, M Cork, A Radin, Q Zhang, B Akinlade, A Gadkari, L Eckert, T Hultsch, Z Chen, G Pirozzi, N M H Graham, B Shumel
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely-used, potent immunosuppressant for AD. CsA is not effective in all patients, and side effects limit its use. Dupilumab, a fully human anti-interleukin (IL)-4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the E.U. for the treatment of adults with moderate-to-severe AD...
November 28, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29191053/diagnosis-and-management-of-conjunctivitis-for-the-dermatologist
#19
Melinda Gooderham, Julian McDonald, Kim Papp
Atopic dermatitis is a chronic, sometimes relapsing inflammatory skin condition that presents with pruritus and characteristic skin manifestations. Conjunctivitis is a common ocular comorbidity affecting almost half of patients with the risk increasing with atopic dermatitis severity. Recent targeted biologic therapies that successfully treat atopic skin disease, including dupilumab, which blocks interleukin (IL)-4 and IL-13, as well as agents that block IL-13 alone, have been associated with an increased rate of conjunctivitis in clinical trials...
November 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29182975/adverse-events-of-dupilumab-in-adults-with-moderate-to-severe-atopic-dermatitis-a-meta-analysis
#20
Zuzhen Ou, Chao Chen, Aijun Chen, Yao Yang, Weikang Zhou
BACKGROUND: Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, inhibits the signals of interleukin-4 and interleukin-13, and has also shown significant efficacy in patients with moderate-to-severe atopic dermatitis (AD), while the effect of it on adverse events remains controversial. OBJECTIVE: To assess the influence of dupilumab on adverse events in adults with moderate-to-severe AD. METHOD: Randomised controlled trials (RCTs) that compared dupilumab with a placebo for patients with moderate-to-severe AD were searched in the MEDLINE, EMBASE, Web of Science and Cochrane databases...
January 2018: International Immunopharmacology
keyword
keyword
25750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"